Tuberculosis Clinical Trial
Official title:
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study With a Food Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
Verified date | September 2019 |
Source | Global Alliance for TB Drug Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to evaluate the safety and tolerability of single oral doses of TBA‐354 when administered to healthy adult subjects.
Status | Completed |
Enrollment | 48 |
Est. completion date | June 2015 |
Est. primary completion date | June 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years to 50 Years |
Eligibility |
Inclusion Criteria: Subjects must fulfill all of the following inclusion criteria and none of the exclusion criteria to be eligible for participation in the study, unless otherwise specified. Subjects must continue to meet all inclusion criteria to be able to participate in the Food Effect study. 1. Healthy adult male and females of non-childbearing potential, 19 to 50 years of age (inclusive) at the time of screening. 2. Body mass index (BMI) = 18.5 and = 32.0 (kg/m2) and a body weight of no less than 50 kg. 3. Medically healthy with no clinically significant screening results (e.g., laboratory profiles, medical histories, vital signs, electrocardiograms (ECGs), physical examination) as deemed by the Principal Investigator. 4. No use of tobacco or nicotine containing products (including smoking cessation products), for a minimum of 6 months prior to dosing. 5. Females of non-childbearing potential have undergone one of the following sterilization procedures at least 6 months prior to dosing: i. Hysteroscopic sterilization ii. Bilateral tubal ligation or bilateral salpingectomy iii. Hysterectomy iv. Bilateral oophorectomy v. or be postmenopausal with amenorrhea for at least 1 year prior to the first dose with serumfollicle-stimulating hormone (FSH) levels consistent with postmenopausal status at screening. 6. Non-vasectomized males (or males vasectomized less than 120 days prior to study start), must agree to the following during study participation and for 90 days following the last administration of study drug: 1. use a condom with spermicide while engaging in sexual activity or be sexually abstinent 2. not donate sperm during this time. In the event the sexual partner is surgically sterile, use of a condom with spermicide is not necessary. None of the restrictions listed above are required for vasectomized males whose procedure was performed more than 120 days prior to study start. 7. Willing to answer inclusion and exclusion criteria questionnaire at check-in. 8. Subject understands study procedures and provides written informed consent for the trial. 9. Be able to comply with the protocol and the assessments therein. Exclusion Criteria: Subjects will be excluded from the study if there is evidence of any of the following criteria at screening or check-in, as appropriate. Subjects must continue to meet none of the Exclusion Criteria in order to participate in the Food Effect study. 1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease. 2. History of any illness that, in the opinion of the Principal Investigator, might confound the results of the study or poses an additional risk to the subject by their participation in the study. 3. Surgery within the past 90 days prior to dosing as determined by the Principal Investigator to be clinically relevant. 4. History or presence of alcoholism or drug abuse within the past 2 years. 5. Hypersensitive or idiosyncratic reactions to compounds related to TBA-354 (e.g., nitroimidazoles such as metronidazole, etc.). 6. Female subjects who are pregnant or lactating. 7. Positive results for the urine drug/alcohol screen at screening or check-in. 8. Positive urine cotinine at screening. 9. Positive results at screening for Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HBsAg), or Hepatitis C antibodies (HCV). 10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening. 11. Heart rate is lower than 40 bpm or higher than 99 bpm at screening. 12. Any clinically significant ECG abnormality at Screening (as deemed by the Principal Investigator and the Sponsor's Medical Monitor). NOTE: The following can be considered not clinically significant without consulting Sponsor's Medical Monitor: i. Mild first degree A-V block (P-R interval <0.23 sec) ii. Right or left axis deviation iii. Incomplete right bundle branch block iv. Isolated left anterior fascicular block (left anterior hemiblock) in younger athletic subjects 13. QTcF interval >450 msec for males or >470 msec for females (the average value for the replicate ECG at screening and Check-In), or history of prolonged QT syndrome. 14. Family history of Long-QT Syndrome or sudden death without a preceding diagnosis of a condition that could be causative of sudden death (such as known coronary artery disease, congestive heart failure or terminal cancer). 15. History of one or any combination of, the following: 1. Seizures or seizure disorders, (excluding febrile seizures of childhood). 2. Brain trauma or brain surgery. 3. Any serious disorder of the CNS or related neurological system, particularly one that may lower the seizure threshold. 16. Use of any prescription medication within 14 days prior to dosing. 17. Use of any over-the-counter (OTC) medication, including herbal products and vitamins, within the 7 days prior to dosing. Up to 2 grams per day of acetaminophen is allowed at the discretion of the Principal Investigator. 18. Use of any drugs or substances known to be significant inhibitors of CYP enzymes and/or significant inhibitors or substrates of P-gp and/or OATP within 14 days prior to the first dose of study drug. 19. Use of any drugs or substances known to be inducers of CYP enzymes and/or P-gp, including St. John's Wort, within 28 days prior to the first dose of study drug. 20. Use of any drugs or substance known to lower the seizure threshold. 21. Blood donation or significant blood loss within 56 days prior to dosing. 22. Plasma donation within 7 days prior to dosing. 23. Participation in another clinical trial within 28 days prior to dosing. 24. Prior treatment with investigational products PA-824 or OPC-67683. 25. Consumption of the following prior to dosing period: 1. Alcohol 48 hours prior to dosing 2. Grapefruit/Mandarin Oranges 10 days prior to dosing 3. Caffeine/Xanthine 24 hours prior to dosing |
Country | Name | City | State |
---|---|---|---|
United States | Celerion | Lincoln | Nebraska |
Lead Sponsor | Collaborator |
---|---|
Global Alliance for TB Drug Development |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint of the study will be the number and severity of treatment emergent adverse events (TEAEs) following single doses of TBA-354 and placebo. | Day 1, 2, 4, 5, 6, 7, 14 | ||
Secondary | Pharmacokinetics of TBA-354 in plasma following single oral doses. Cmax, AUC0-24 | Tmax: Time of the maximum drug concentration (obtained without interpolation). Cmax: Maximum observed drug concentration. AUC0-24: Area under concentration time curve 0 to 24 hours | Day 1 (Hour 0, 1, 2, 4, 6, 7, 8, 12, 16), Day 2 (Hour 20, 24, 30, 36, 42), Follow up (Hour 72, 96, 120, 144) | |
Secondary | Effect of food on the Pharmacokinetics parameters of TBA-354 in plasma following an intermediate single oral dose. Cmax, AUC0-24 | Tmax: Time of the maximum drug concentration (obtained without interpolation). Cmax: Maximum observed drug concentration. AUC0-24: Area under concentration time curve 0 to 24 hours | Day 1 (Hour 0, 1, 2, 4, 6, 7, 8, 12, 16), Day 2 (Hour 20, 24, 30, 36, 42), Follow up (Hour 72, 96, 120, 144) | |
Secondary | Number of subjects/time points with abnormal findings in safety electrocardiogram | Calculated in terms of QT corrected for heart rate according to Fridericia's corrected formula (QTcF) outliers (QTcF > 450, > 480, and > 500 msec; and change-from-baseline QTcF > 30 and > 60 msec). | Screening; Day 1 (Hour 0, 1, 2, 4, 6, 8, 12, 16); Day 2 Hour 20, 24, 30, 36 and 48; Follow up Hour 144 | |
Secondary | Placebo-corrected safety electrocardiogram Change-from-baseline heart rate | Change-from-baseline heart rate, QT corrected for heart rate according to Fridericia's corrected formula (QTcF), PR, QRS, QT, and incidence of abnormal T-wave morphology from cardiodynamic electrocardiograms extracted from the pre-specified time points. | Screening; Day 1 (Hour 0, 1, 2, 4, 6, 8, 12, 16); Day 2 Hour 20, 24, 30, 36 and 48; Follow up Hour 144 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |